Immune Determinants of the Association Between Tumor Mutational Burden and Immunotherapy Response Across Cancer Types

Overview

Journal Cancer Res

Specialty Oncology

Date 2022 Apr 6

PMID 35385572

Authors

Neelam Sinha

Sanju Sinha

Cristina Valero

Alejandro A Schaffer

Kenneth Aldape

Kevin Litchfield

Timothy A Chan

Luc G T Morris

Eytan Ruppin

Affiliations

Soon will be listed here.

Abstract

Significance: This study uncovers immune-related factors that may modulate the relationship between high tumor mutational burden and ICI response, which can help prioritize cancer types for clinical trials.

Citing Articles

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma.

Yang L, Feng Y, Liu X, Zhang Q, Liu Y, Zhang X Invest New Drugs. 2025; .

PMID: 39934438 DOI: 10.1007/s10637-024-01495-3.

The expression landscape and clinical significance of methyltransferase-like 17 in human cancer and hepatocellular carcinoma: a pan-cancer analysis using multiple databases.

Ding Y, Feng M, Chi W, Wang X, An B, Liu K Cancer Cell Int. 2025; 25(1):15.

PMID: 39825447 PMC: 11740614. DOI: 10.1186/s12935-024-03616-7.

Identifying biomarkers to predict immune-checkpoint therapy response-is it a reality or a distant dream?.

Ashok Kumar P Transl Cancer Res. 2024; 13(11):6590-6593.

PMID: 39697699 PMC: 11651762. DOI: 10.21037/tcr-24-1383.

Unveiling the role of Pleckstrin-2 in tumor progression and immune modulation: insights from a comprehensive pan-cancer analysis with focus on lung cancer.

Yin E, Liu C, Yao Y, Luo Y, Yang Y, Tang X Mol Biomed. 2024; 5(1):59.

PMID: 39546161 PMC: 11568116. DOI: 10.1186/s43556-024-00225-8.

Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting.

Jiao L, Tao Y, Ding H, Wu F, Liu Y, Li C 3 Biotech. 2024; 14(9):215.

PMID: 39220827 PMC: 11358563. DOI: 10.1007/s13205-024-04053-z.

References

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

Valero C, Lee M, Hoen D, Zehir A, Berger M, Seshan V . Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncol. 2021; 7(5):739-743. PMC: 7893543. DOI: 10.1001/jamaoncol.2020.7684. View

Jardim D, Goodman A, Gagliato D, Kurzrock R . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020; 39(2):154-173. PMC: 7878292. DOI: 10.1016/j.ccell.2020.10.001. View

Hugo W, Zaretsky J, Sun L, Song C, Moreno B, Hu-Lieskovan S . Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016; 165(1):35-44. PMC: 4808437. DOI: 10.1016/j.cell.2016.02.065. View

Valero C, Lee M, Hoen D, Wang J, Nadeem Z, Patel N . The association between tumor mutational burden and prognosis is dependent on treatment context. Nat Genet. 2021; 53(1):11-15. PMC: 7796993. DOI: 10.1038/s41588-020-00752-4. View

Lin Y, Xu J, Lan H . Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019; 12(1):76. PMC: 6626377. DOI: 10.1186/s13045-019-0760-3. View

Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y . Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020; 11(1):4946. PMC: 7532211. DOI: 10.1038/s41467-020-18742-9. View

Hoadley K, Yau C, Hinoue T, Wolf D, Lazar A, Drill E . Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 2018; 173(2):291-304.e6. PMC: 5957518. DOI: 10.1016/j.cell.2018.03.022. View

Valero C, Lee M, Hoen D, Weiss K, Kelly D, Adusumilli P . Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021; 12(1):729. PMC: 7851155. DOI: 10.1038/s41467-021-20935-9. View

10.

Lee J, Ruppin E . Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. JAMA Oncol. 2019; 5(11):1614-1618. PMC: 6707018. DOI: 10.1001/jamaoncol.2019.2311. View

11.

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

12.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

13.

Litchfield K, Reading J, Puttick C, Thakkar K, Abbosh C, Bentham R . Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021; 184(3):596-614.e14. PMC: 7933824. DOI: 10.1016/j.cell.2021.01.002. View

14.

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

15.

McGrail D, Pilie P, Rashid N, Voorwerk L, Slagter M, Kok M . High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021; 32(5):661-672. PMC: 8053682. DOI: 10.1016/j.annonc.2021.02.006. View

16.

Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L . Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019; 25(12):1916-1927. PMC: 6898788. DOI: 10.1038/s41591-019-0654-5. View

17.

Wang K, Patkar S, Lee J, Gertz E, Robinson W, Schischlik F . Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti-PD-1 Therapy. Cancer Discov. 2022; 12(4):1088-1105. PMC: 8983586. DOI: 10.1158/2159-8290.CD-21-0887. View

18.

Joffre O, Nolte M, Sporri R, Reis e Sousa C . Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev. 2009; 227(1):234-47. DOI: 10.1111/j.1600-065X.2008.00718.x. View

19.

Yarchoan M, Hopkins A, Jaffee E . Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017; 377(25):2500-2501. PMC: 6549688. DOI: 10.1056/NEJMc1713444. View

20.

Chan T, Yarchoan M, Jaffee E, Swanton C, Quezada S, Stenzinger A . Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2018; 30(1):44-56. PMC: 6336005. DOI: 10.1093/annonc/mdy495. View